Compare YJ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | China | Australia |
| Employees | N/A | 6 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 186.7M |
| IPO Year | 2019 | 2002 |
| Metric | YJ | KZIA |
|---|---|---|
| Price | $1.99 | $11.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.5M | 263.3K |
| Earning Date | 03-27-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $4.86 |
| 52 Week High | $13.97 | $17.40 |
| Indicator | YJ | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 38.77 |
| Support Level | $1.42 | $7.25 |
| Resistance Level | $2.33 | $14.85 |
| Average True Range (ATR) | 0.33 | 1.15 |
| MACD | -0.14 | -0.30 |
| Stochastic Oscillator | 2.04 | 5.04 |
Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.